Altre lingue EXACT Therapeutics

Azioni

EXTX

NO0010852213

Mercato chiuso - Oslo Bors Altri mercati azionari 16:45:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
6,8 ^NOK	0,00%		-2,86%	-43,33%

19/04	EXACT Therapeutics AS riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI
2023	EXACT Therapeutics AS riporta i risultati degli utili per il semestre conclusosi il 30 giugno 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

EXACT Therapeutics : Successful placement of NOK 25 million share issue	25/04
EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023	19/04
Additional promising clinical data from EXACT Therapeutics' ongoing ACTIVATE study presented at AACR Annual Meeting	10/04
EXACT Therapeutics to Present at 2024 American Association for Cancer Research (AACR) Annual Meeting	06/03
EXACT Therapeutics AS - Share capital increase registered	20/12
EXACT Therapeutics presenting at DNB Nordic Healthcare conference December 14	14/12
EXACT Therapeutics : announces successful placement of NOK 25 million share issue	01/12
EXACT Therapeutics AS: Primary insider notices	01/12
EXACT Therapeutics AS: Private placement successfully placed	30/11
EXACT Therapeutics AS: Contemplated Private Placement	30/11
Exact Therapeutics Wins Regulatory Approvals for Patient Recruitment in Dose Expansion Study	31/10/23
EXACT Therapeutics receives regulatory approval to start recruitment of patients at Oslo University hospital	31/10/23
EXACT Therapeutics AS - Issuance of share options	16/10/23
EXACT Therapeutics CEO Dr Per Walday to participate in international Drug Delivery panel	12/10/23
EXACT Therapeutics AS Reports Earnings Results for the Half Year Ended June 30, 2023	28/09/23
EXACT Therapeutics : Interim Report 2023	28/09/23
EXACT Therapeutics announces first half 2023 interim results	28/09/23
EXACT Therapeutics announces appointment of Caspar Foghsgaard as SVP Commercial & Business Development	27/09/23
EXACT Therapeutics AS Announces Appointment of Caspar Foghsgaard as SVP Commercial & Business Development Effective 1 November 2023	27/09/23
Exact Therapeutics Jumps 13% After Positive Outcomes From Acoustic Cluster Therapy Trial	26/09/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue EXACT Therapeutics

Azioni

EXTX

NO0010852213

Altre lingue

Filtri